Home › Non-Small Cell Lung Cancer › NCT07218601
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer
RecruitingPhase 2
Electronic Nose (E-nose) Technology to Assess Pathologic Response and Post- Treatment Progression for Non-small Cell Lung Cancer: a Phase II Study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥18 * Untreated clinical stage I NSCLC amenable to upfront surgery * Untreated stage II to IIIB NSCLC amenable to neoadjuvant treatment followed by surgery * ECOG Performance Status of ≤2 Of note, the E-nose is a completely noninvasive technology (only breath samples are collected). Therefore, this intervention would have no effects on a developing human fetus. There are therefore no requirements for the study population related to contraception or pregnancy testing.
About the study
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.
What is being tested
- Breath sample collection (diagnostic test)
- Research blood collection (diagnostic test)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 60 · Started: Oct 10, 2025
Contact the study team
- Gaetano Rocco, MD · Phone: 212-639-3478
- David Jones, MD · Phone: 212-639-6428
Official record on ClinicalTrials.gov — NCT07218601
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.